# CagriSema > Novo Nordisk’s investigational fixed combination of cagrilintide (amylin) and semaglutide (GLP-1) — two appetite pathways in one weekly injection. - Also known as: Cagrilintide/semaglutide, cagrilintide + semaglutide - Class: Metabolic - FDA approved: No - Canonical page: https://americanpeptide.com/catalog/cagrisema ## Overview CagriSema is not a single molecule but a fixed-dose combination of two peptides already in this catalog: cagrilintide, a long-acting amylin analog, and semaglutide, the GLP-1 agonist. Novo Nordisk pairs the amylin and GLP-1 satiety pathways in one once-weekly injection, betting that two complementary appetite mechanisms together drive more weight loss than either alone. It is investigational and in Phase 3. CagriSema is a combination product, and that is the whole point of it. Rather than engineer a single peptide that hits several receptors — the multi-agonist route taken by tirzepatide and retatrutide — Novo Nordisk co-formulates two of its existing peptides: the amylin analog cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite, but through different receptor systems, so combining them is studied for additive weight effect from a single weekly injection. Because it is a co-formulation, CagriSema has no molecular formula or sequence of its own — its properties are those of its two components, each documented on its own monograph here. It is investigational, studied in the Phase 3 REDEFINE program, where it produced large mean weight reductions in the low-to-mid twenties percent; the results were strong in absolute terms even as they were scrutinized against very high market expectations. It is not FDA-approved. ## Mechanism Co-agonism across two pathways: semaglutide activates the GLP-1 receptor while cagrilintide activates amylin and calcitonin receptors — complementary routes to satiety and slowed gastric emptying. ## Research areas Studied in: Obesity, Type 2 diabetes, Combination metabolic therapy. Guides on this site: - [Weight Loss & Metabolic Health](https://americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss. ## Key research - Two-pathway combination — pairs semaglutide (GLP-1) with cagrilintide (amylin) to engage two distinct satiety systems in one weekly injection. - Not a single molecule — a fixed-dose co-formulation; its chemistry is that of its two component peptides, each catalogued separately here. - Weight reduction — the Phase 3 REDEFINE program reported large mean reductions in the low-to-mid twenties percent. - Combination rationale — an alternative to single multi-agonist peptides, reached by combining two proven components. - Investigational — a Novo Nordisk candidate; not FDA-approved. ## Storage, handling & synthesis **Synthesis.** CagriSema is a co-formulation, not a synthesized molecule: it is manufactured by making its two component peptides — cagrilintide and semaglutide — separately, each to its own spec and certificate of analysis, and combining them at fixed doses. Its quality therefore rests on the identity and purity of two peptides at once, described on their individual monographs. ## FAQs ### What is CagriSema? CagriSema is Novo Nordisk’s investigational fixed combination of two peptides — cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist) — given as one once-weekly injection for weight management. ### Is CagriSema a single peptide? No — it is a co-formulation of two separate peptides (cagrilintide and semaglutide), each with its own monograph here, so it has no single molecular formula. ### How does it compare with tirzepatide? Tirzepatide is one molecule hitting two receptors (GIP + GLP-1); CagriSema instead combines two molecules (amylin + GLP-1). Both aim for additive metabolic effect by different means. ### Is CagriSema approved? No — it is investigational and in Phase 3. This page is a research and educational reference, not medical advice. ## Latest research Recent trials and publications mentioning CagriSema, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily). ### Recent trials - [A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight](https://clinicaltrials.gov/study/NCT07564414) — RECRUITING · PHASE3 · NCT07564414 - [A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term](https://clinicaltrials.gov/study/NCT07011667) — ACTIVE_NOT_RECRUITING · PHASE3 · NCT07011667 - [REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels](https://clinicaltrials.gov/study/NCT05669755) — ACTIVE_NOT_RECRUITING · PHASE3 · NCT05669755 - [A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight](https://clinicaltrials.gov/study/NCT05567796) — ACTIVE_NOT_RECRUITING · PHASE3 · NCT05567796 - [A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both](https://clinicaltrials.gov/study/NCT06534411) — COMPLETED · PHASE3 · NCT06534411 - [A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight](https://clinicaltrials.gov/study/NCT07253285) — RECRUITING · PHASE3 · NCT07253285 --- Source: AmericanPeptide.com — https://americanpeptide.com/catalog/cagrisema Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com. Research reference only — computational and educational content, not medical advice.